Background: Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the role of hydroxychloroquine on respiratory viral loads.
Patients and methods: French Confirmed COVID-19 patients were included in a single arm protocol from early March to March 16th, to receive 600mg of hydroxychloroquine daily and their viral load in nasopharyngeal swabs was tested daily in a hospital setting. Depending on their clinical presentation, azithromycin was added to the treatment. Untreated patients from another center and cases refusing the protocol were included as negative controls. Presence and absence of virus at Day6-post inclusion was considered the end point.
Results: Six patients were asymptomatic, 22 had upper respiratory tract infection symptoms and eight had lower respiratory tract infection symptoms. Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported of untreated patients in the literature. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination.
Conclusion: Despite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.
Keywords: 2019-nCoV; COVID-19; SARS-CoV-2; azithomycin; clinical trial; hydroxychloroquine.
Copyright © 2020. Published by Elsevier B.V.
Conflict of interest statement
Declaration of Competing Interest N/A
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?Int J Antimicrob Agents. 2020 Mar 11:105938. doi: 10.1016/j.ijantimicag.2020.105938. Online ahead of print. Int J Antimicrob Agents. 2020. PMID: 32171740 Free PMC article.
Features, Evaluation and Treatment Coronavirus (COVID-19).2020 Mar 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. StatPearls. 2020 Jan–. PMID: 32150360 Free Books & Documents. Review.
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).Clin Infect Dis. 2020 Mar 9:ciaa237. doi: 10.1093/cid/ciaa237. Online ahead of print. Clin Infect Dis. 2020. PMID: 32150618 Free PMC article.
The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients.J Med Virol. 2020 Feb 27. doi: 10.1002/jmv.25728. Online ahead of print. J Med Virol. 2020. PMID: 32104915 Review.
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.J Microbiol Immunol Infect. 2020 Mar 4:S1684-1182(20)30040-2. doi: 10.1016/j.jmii.2020.02.012. Online ahead of print. J Microbiol Immunol Infect. 2020. PMID: 32173241 Review.
- Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020 Feb 17 [Epub ahead of print]
- Wang LS, Wang YR, Ye DW, Liu QQ. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence”. Int J Antimicrob Agents. 2020 [Epub ahead of print]
- WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. [https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020]
- Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020 Feb 24 [Epub ahead of print]
- Santé Publique France. Infection au nouveau Coronavirus (SARS-CoV-2), COVID-19, France et Monde [https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/articles/infection-au-nouveau-coronavirus-sars-cov-2-covid-19-france-et-monde]